JSAM
J. Safra Asset Management Portfolio holdings
AUM
$1.38B
This Quarter Return
+12.14%
1 Year Return
+16.76%
3 Year Return
+74.03%
5 Year Return
+124.37%
10 Year Return
–
AUM
$1.38B
AUM Growth
+$1.38B
(+15%)
Cap. Flow
+$65.2M
Cap. Flow
% of AUM
4.71%
Top 10 Holdings %
Top 10 Hldgs %
70.85%
Holding
356
New
51
Increased
132
Reduced
91
Closed
30
Top Buys
Top Sells
| 1 |
SPDR S&P Biotech ETF
XBI
|
$25M |
| 2 |
iShares Core S&P Small-Cap ETF
IJR
|
$1.46M |
| 3 |
SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
|
$1.07M |
| 4 |
Tesla
TSLA
|
$423K |
| 5 |
NXP Semiconductors
NXPI
|
$367K |
Sector Composition
| 1 | Technology | 2.24% |
| 2 | Communication Services | 1.04% |
| 3 | Financials | 0.69% |
| 4 | Consumer Discretionary | 0.67% |
| 5 | Healthcare | 0.43% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
276
ArcBest
ARCB
$1.66B
| $6.57K | ﹤0.01% |
87
-36
| -29% | -$2.72K |
|
277
Celldex Therapeutics
CLDX
$1.5B
| $4.77K | ﹤0.01% |
235
-95
| -29% | -$1.93K |
|
278
American Eagle Outfitters
AEO
$2.32B
| $4.12K | ﹤0.01% |
417
-167
| -29% | -$1.65K |
|
279
First Northwest Bancorp
FNWB
$66.1M
| $3.55K | ﹤0.01% |
469
-188
| -29% | -$1.42K |
|
280
Penumbra
PEN
$10.5B
| $3.33K | ﹤0.01% |
13
| – | – |
|
281
Caleres
CAL
$502M
| $2.92K | ﹤0.01% |
233
-85
| -27% | -$1.07K |
|
282
Masimo
MASI
$7.4B
| $2.52K | ﹤0.01% |
15
| – | – |
|
283
Insulet
PODD
$24.2B
| $2.51K | ﹤0.01% |
8
-1
| -11% | -$313 |
|
284
Alnylam Pharmaceuticals
ALNY
$59.3B
| $2.26K | ﹤0.01% |
7
| – | – |
|
285
CVS Health
CVS
$93.5B
| $2.19K | ﹤0.01% |
32
+19
| +146% | +$1.3K |
|
286
Exact Sciences
EXAS
$9.04B
| $1.88K | ﹤0.01% |
35
+4
| +13% | +$215 |
|
287
Stryker
SYK
$149B
| $1.57K | ﹤0.01% |
4
| – | – |
|
288
Molina Healthcare
MOH
$9.92B
| $1.49K | ﹤0.01% |
5
+3
| +150% | +$891 |
|
289
Veeva Systems
VEEV
$44.2B
| $1.42K | ﹤0.01% |
5
| – | – |
|
290
Gilead Sciences
GILD
$140B
| $1.11K | ﹤0.01% |
10
+1
| +11% | +$111 |
|
291
Privia Health
PRVA
$2.84B
| $1.08K | ﹤0.01% |
49
| – | – |
|
292
Legend Biotech
LEGN
$6.37B
| $1.07K | ﹤0.01% |
31
+3
| +11% | +$104 |
|
293
Royalty Pharma
RPRX
$15.6B
| $933 | ﹤0.01% |
26
| – | – |
|
294
Glaukos
GKOS
$5.38B
| $913 | ﹤0.01% |
9
+1
| +13% | +$101 |
|
295
Surgery Partners
SGRY
$2.89B
| $790 | ﹤0.01% |
36
| – | – |
|
296
Nuvalent
NUVL
$5.44B
| $717 | ﹤0.01% |
9
+2
| +29% | +$159 |
|
297
Inspire Medical Systems
INSP
$2.78B
| $662 | ﹤0.01% |
5
| – | – |
|
298
Merus
MRUS
$5.02B
| $636 | ﹤0.01% |
12
| – | – |
|
299
Soleno Therapeutics
SLNO
$3.61B
| $583 | ﹤0.01% |
7
| – | – |
|
300
Centene
CNC
$14.5B
| $540 | ﹤0.01% |
+10
| New | +$540 |
|